Previous close | 22.64 |
Open | 22.60 |
Bid | 22.35 x 1000 |
Ask | 22.32 x 900 |
Day's range | 21.33 - 22.91 |
52-week range | 13.47 - 33.09 |
Volume | |
Avg. volume | 371,356 |
Market cap | 974.619M |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.25 |
Earnings date | 14 Mar 2022 - 18 Mar 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 41.56 |
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
34% overall response rate in 79 evaluable patients with measurable disease9.1 months median duration of responseTumor reduction in 70% of patientsZeno observed to be very well-toleratedPotential new standard of care for patients with NRG1+ cancerInvestor call to discuss clinical results on Sunday, June 5 at 6:00 p.m. CT UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 05, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology com
The mean of analysts' price targets for Merus N.V. (MRUS) points to an 113.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.